Our results showed that IL-17-neutralizing antibody administration decreases the inflammatory response mediated by Th17 cytokines in the lungs, mitigating the functional and structural changes induced by CS exposure in an experimental model of COPD. This evidence concerns the gene IL17A and chronic obstructive pulmonary disease.